Guard Therapeutics International Overview
- Year Founded
-
2008
- Status
-
Acquired/Merged
- Employees
-
5
- Latest Deal Type
-
M&A
Guard Therapeutics International General Information
Description
Guard Therapeutics International AB is engaged in developing and commercializing the lead drug candidate ROSgard, and thereby contribute to the better and less harmful treatment of acute kidney injuries.
Contact Information
Corporate Office
- Nybrogatan 34, 2nd floor
- 114 39 Stockholm
- Sweden
Corporate Office
- Nybrogatan 34, 2nd floor
- 114 39 Stockholm
- Sweden
Guard Therapeutics International Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 27-Jul-2026 | Completed | Generating Revenue | |||
| 6. 2PO | 17-Jun-2024 | Completed | Generating Revenue | |||
| 5. 2PO | 20-Oct-2021 | Cancelled | Generating Revenue | |||
| 4. PIPE | 17-Jun-2019 | Completed | Generating Revenue | |||
| 3. IPO | 03-Apr-2013 | Completed | Generating Revenue | |||
| 2. Early Stage VC | Completed | Startup | ||||
| 1. Accelerator/Incubator | Completed | Startup |
Guard Therapeutics International Patents
Guard Therapeutics International Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024219294-A1 | Alpha-1-microglobulin derived peptide fragments and uses thereof | Pending | 08-Feb-2023 | ||
| EP-4661893-A1 | Alpha-1-microglobulin derived peptide fragments and uses thereof | Pending | 08-Feb-2023 | ||
| WO-2024165674-A1 | Alpha-1-microglobulin derived peptide fragments and uses thereof | Inactive | 08-Feb-2023 | ||
| JP-2026507475-A | Alpha-1-microglobulin-derived peptide fragments and uses thereof | Pending | 08-Feb-2023 | ||
| JP-2021501750-A | Use of alpha-1-microglobulin for bone marrow cell protection | Inactive | 03-Nov-2017 | A61K38/1722 |
Guard Therapeutics International Signals
Guard Therapeutics International Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Industrifonden | Venture Capital | Minority | ||
| LU Ventures (Lund) | Corporate Venture Capital | Minority | ||
| M2 Asset Management | Asset Manager | Minority | ||
| SmiLe Incubator | Accelerator/Incubator | |||
| Unionen | Corporation | Minority |
Guard Therapeutics International Investments & Acquisitions (2)
Guard Therapeutics International’s most recent deal was a Reverse Merger with Disruptive Materials. The deal was made on 11-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Disruptive Materials | 11-Jun-2026 | Reverse Merger | Specialty Chemicals | ||
| ImmuneBiotech | 16-Feb-2018 | Angel (individual) | Drug Discovery |
Guard Therapeutics International ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Guard Therapeutics International FAQs
-
When was Guard Therapeutics International founded?
Guard Therapeutics International was founded in 2008.
-
Where is Guard Therapeutics International headquartered?
Guard Therapeutics International is headquartered in Stockholm, Sweden.
-
What is the size of Guard Therapeutics International?
Guard Therapeutics International has 5 total employees.
-
What industry is Guard Therapeutics International in?
Guard Therapeutics International’s primary industry is Drug Discovery.
-
Is Guard Therapeutics International a private or public company?
Guard Therapeutics International is a Private company.
-
What is Guard Therapeutics International’s current revenue?
The current revenue for Guard Therapeutics International is .
-
How much funding has Guard Therapeutics International raised over time?
Guard Therapeutics International has raised $2.86M.
-
Who are Guard Therapeutics International’s investors?
Industrifonden, LU Ventures (Lund), M2 Asset Management, SmiLe Incubator, and Unionen have invested in Guard Therapeutics International.
-
When was Guard Therapeutics International acquired?
Guard Therapeutics International was acquired on 27-Jul-2026.
-
Who acquired Guard Therapeutics International?
Guard Therapeutics International was acquired by Disruptive Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process